Alimentary Pharmacology & Therapeutics

© 2013 Blackwell Publishing Ltd

Cover image for Alimentary Pharmacology & Therapeutics

April 2013

Volume 37, Issue 7

Pages 659–766

  1. REVIEW ARTICLE

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients (pages 659–671)

      D. Joshi, I. Carey and K. Agarwal

      Article first published online: 21 FEB 2013 | DOI: 10.1111/apt.12260

  2. META-ANALYSIS

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis (pages 672–679)

      M. Ney, B. Vandermeer, S. J. V. van Zanten, M. M. Ma, L. Gramlich and P. Tandon

      Article first published online: 20 FEB 2013 | DOI: 10.1111/apt.12252

  3. RANDOMISED CLINICAL TRIAL

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo-controlled study (pages 680–690)

      W. Kruis, E. Meier, M. Schumacher, O. Mickisch, R. Greinwald and R. Mueller, the German SAG-20 Study Group

      Article first published online: 17 FEB 2013 | DOI: 10.1111/apt.12248

    2. You have full text access to this OnlineOpen article
      Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension (pages 691–702)

      C. M. Seiler, J. Izbicki, L. Varga-Szabó, L. Czakó, J. Fiók, C. Sperti, M. M. Lerch, R. Pezzilli, G. Vasileva, Á. Pap, M. Varga and H. Friess

      Article first published online: 5 FEB 2013 | DOI: 10.1111/apt.12236

  4. ALCOHOL AND HEPATITIS C

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C (pages 703–709)

      Z. M. Younossi, L. Zheng, M. Stepanova, C. Venkatesan and H. M. Mir

      Article first published online: 24 FEB 2013 | DOI: 10.1111/apt.12265

  5. HEPATITIS B

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B (pages 710–719)

      J. L. Hartono, M. O. Aung, Y. Y. Dan, M. Gowans, K. Lim, Y. M. Lee, G. H. Lee, H. C. Low, P. S. Tan, M. A. Thwin, C. Soon, L.-L. Chiu, M. J. Khoo, E. Koay and S. G. Lim

      Article first published online: 21 FEB 2013 | DOI: 10.1111/apt.12251

  6. NAFLD

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease (pages 720–729)

      M. D. Beaton, S. Chakrabarti, M. Levstik, M. Speechley, P. Marotta and P. Adams

      Article first published online: 26 FEB 2013 | DOI: 10.1111/apt.12255

  7. GASTRO-OESOPHAGEAL REFLUX DISEASE

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. The impact of intensifying acid suppression on sleep disturbance related to gastro-oesophageal reflux disease in primary care (pages 730–737)

      P. Moayyedi, R. Hunt, D. Armstrong, Y. Lei, M. Bukoski and R. White

      Article first published online: 21 FEB 2013 | DOI: 10.1111/apt.12254

  8. RISKS OF ASPIRIN

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      The aspirin cardiovascular/gastrointestinal risk calculator - a tool to aid clinicians in practice (pages 738–748)

      A. Lanas, M. Polo-Tomás and R. Casado-Arroyo

      Article first published online: 17 FEB 2013 | DOI: 10.1111/apt.12240

  9. INVITED COMMENTARIES

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Commentary: psychoeducation in the irritable bowel syndrome - talking the talk (page 749)

      E. M. M. Quigley

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12220

    2. You have free access to this content
      Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument (page 750)

      M. R. Kappus and J. S. Bajaj

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12233

    3. You have free access to this content
      Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument – authors’ reply (pages 750–751)

      S. L. Szeinbach, L. Gazzuola Rocca, D. Littlefield and B. P. Yawn

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12244

  10. LETTERS TO THE EDITORS

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? (page 752)

      A. Tursi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12216

    2. You have free access to this content
      Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply (pages 752–753)

      C. Reenaers, E. Louis, J. Belaiche, L. Seidel, S. Keshav and S. Travis

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12245

    3. You have free access to this content
      Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data (pages 753–754)

      K. Appelhans, R. Najeeullah and V. Frankos

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12217

    4. You have free access to this content
      Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data – authors' reply (pages 754–755)

      K. R. Reddy and C. Bunchorntavakul

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12242

    5. You have free access to this content
      Letter: an allergic phenotype in patients with eosinophilic oesophagitis and asthma (pages 755–756)

      H. Philpott, P. R. Gibson, F. Thien and S. Nandurkar

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12225

    6. You have free access to this content
      Letter: an allergic phenotype in patients with eosinophilic oesophagitis and asthma – authors' reply (pages 756–757)

      K. N. Harer and D. A. Katzka

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12241

    7. You have free access to this content
      Letter: curing Helicobacter pylori infection in a clinical setting (pages 757–758)

      A. Tursi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12226

    8. You have free access to this content
      Letter: curing Helicobacter pylori infection in a clinical setting – authors' reply (pages 758–759)

      F. Thirriot and C. Y. Tay

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12250

    9. You have free access to this content
      Letter: complications of coeliac disease despite a gluten-free diet (pages 759–760)

      A. Tursi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12227

    10. You have free access to this content
      Letter: mucosal healing and mortality in coeliac disease (pages 760–761)

      F. Fernández-Bañares, M. Esteve and J. P. Gisbert

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12229

    11. You have free access to this content
      Letter: Adnab-9 as a potential non-invasive biomarker for prediction of malignancy in coeliac disease (pages 761–762)

      S. Kadauke, A. Picarelli, M. Di Tola, R. K. Parikh, P. Naylor, W.-L. Zhou, J. Bowman, D. Bullock and M. Tobi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12231

    12. You have free access to this content
      Letter: complications of coeliac disease despite a gluten-free diet – authors' reply (pages 762–763)

      B. Lebwohl, F. Granath, A. Ekbom, S. M. Montgomery, J. A. Murray, A. Rubio-Tapia, P. H. R. Green and J. F. Ludvigsson

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12243

    13. You have free access to this content
      Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice? (pages 763–764)

      A. Tursi, W. Elisei, M. Picchio and A. Penna

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12238

    14. You have free access to this content
      Letter: gastric cancer and pernicious anaemia – often Helicobacter pylori in disguise (pages 764–765)

      M. Rugge, M. Fassan, M. Pizzi and D. Y. Graham

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12239

    15. You have free access to this content
      Letter: gastric cancer and pernicious anaemia - often Helicobacter pylori in disguise; authors' reply (pages 765–766)

      E. Lahner and B. Annibale

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12246

SEARCH

SEARCH BY CITATION